JPWO2020116498A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020116498A5
JPWO2020116498A5 JP2020559959A JP2020559959A JPWO2020116498A5 JP WO2020116498 A5 JPWO2020116498 A5 JP WO2020116498A5 JP 2020559959 A JP2020559959 A JP 2020559959A JP 2020559959 A JP2020559959 A JP 2020559959A JP WO2020116498 A5 JPWO2020116498 A5 JP WO2020116498A5
Authority
JP
Japan
Prior art keywords
cxcr3 ligand
cxcr3
sequence
amino acid
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559959A
Other languages
English (en)
Japanese (ja)
Other versions
JP7438975B2 (ja
JPWO2020116498A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/047382 external-priority patent/WO2020116498A1/ja
Publication of JPWO2020116498A1 publication Critical patent/JPWO2020116498A1/ja
Publication of JPWO2020116498A5 publication Critical patent/JPWO2020116498A5/ja
Application granted granted Critical
Publication of JP7438975B2 publication Critical patent/JP7438975B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559959A 2018-12-04 2019-12-04 Cxcr3リガンド Active JP7438975B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018227353 2018-12-04
JP2018227353 2018-12-04
PCT/JP2019/047382 WO2020116498A1 (ja) 2018-12-04 2019-12-04 Cxcr3リガンド

Publications (3)

Publication Number Publication Date
JPWO2020116498A1 JPWO2020116498A1 (ja) 2021-10-14
JPWO2020116498A5 true JPWO2020116498A5 (cg-RX-API-DMAC7.html) 2022-12-07
JP7438975B2 JP7438975B2 (ja) 2024-02-27

Family

ID=70974705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559959A Active JP7438975B2 (ja) 2018-12-04 2019-12-04 Cxcr3リガンド

Country Status (4)

Country Link
US (2) US12624077B2 (cg-RX-API-DMAC7.html)
EP (1) EP3892330A4 (cg-RX-API-DMAC7.html)
JP (1) JP7438975B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020116498A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3892330A4 (en) 2018-12-04 2022-10-26 Chugai Seiyaku Kabushiki Kaisha CXCR3 LIGAND
CA3194929A1 (en) * 2020-06-21 2021-12-30 Technion Research & Development Foundation Limited Modified cxcl10 for immunotherapy of cancer diseases
US20230242606A1 (en) * 2020-06-21 2023-08-03 Technion Research & Development Foundation Limited Cxcl9 and variants thereof for immunotherapy of cancer diseases
WO2023120643A1 (ja) 2021-12-23 2023-06-29 中外製薬株式会社 Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。
CN121338000B (zh) * 2025-11-13 2026-08-04 中山大学 Rab30-dt抑制剂在制备预防和治疗肿瘤的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028474A2 (en) 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
US7091310B2 (en) * 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
WO2003082335A1 (fr) * 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Co., Ltd. Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20090131312A1 (en) 2005-05-18 2009-05-21 Lawrence Blatt Non-natural chemokine receptor ligands and methods of use thereof
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012172336A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory skin diseases
EP3096777B1 (en) 2014-01-21 2021-01-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Goblet cell replacement therapy
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
EP3892330A4 (en) 2018-12-04 2022-10-26 Chugai Seiyaku Kabushiki Kaisha CXCR3 LIGAND
WO2021038033A1 (en) 2019-08-29 2021-03-04 Antagonis Biotherapeutics Gmbh T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
WO2023120643A1 (ja) 2021-12-23 2023-06-29 中外製薬株式会社 Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。

Similar Documents

Publication Publication Date Title
KR100227167B1 (ko) 인체혈청알부민의 n-말단 단편을 함유하는 융합단백질
EP0399666B1 (en) Fusion proteins containing n-terminal fragments of human serum albumin
JP2022503959A5 (cg-RX-API-DMAC7.html)
JP2009540801A5 (cg-RX-API-DMAC7.html)
CN104211769B (zh) 一种小分子抗体亲和肽及其应用
JP2015212284A5 (cg-RX-API-DMAC7.html)
JP2009268467A5 (cg-RX-API-DMAC7.html)
JP2016521539A5 (cg-RX-API-DMAC7.html)
JP2008507298A5 (cg-RX-API-DMAC7.html)
JP2022509517A5 (cg-RX-API-DMAC7.html)
JP2014503198A5 (cg-RX-API-DMAC7.html)
JP2015514132A5 (cg-RX-API-DMAC7.html)
JP2012516140A5 (cg-RX-API-DMAC7.html)
CN103214563B (zh) 一种性能改进的重组金黄色葡萄球菌蛋白a亲和配基及其构建方法
JP2011521661A5 (cg-RX-API-DMAC7.html)
Park et al. The Ustilago maydis virally encoded KP1 killer toxin
JP2014047156A5 (cg-RX-API-DMAC7.html)
JP2020509770A5 (cg-RX-API-DMAC7.html)
CN103755810B (zh) 一种长效hiv‐1膜融合抑制剂
JP2010535504A5 (cg-RX-API-DMAC7.html)
JP2004532037A5 (cg-RX-API-DMAC7.html)
CN104163850A (zh) 一种小分子抗体亲和肽及其应用
JP2023512683A5 (cg-RX-API-DMAC7.html)
CN120209098B (zh) Rsv f蛋白可溶片段、自源三聚体结构域及其应用
Peumans et al. The tomato lectin consists of two homologous chitin-binding modules separated by an extensin-like linker